In a recent study in untrained men and women with abdominal obesity, inhibiting IL‐6 activity (using the IL‐6 receptor antibody tocilizumab) attenuated the increase in LV mass observed after a 12‐week high‐intensity interval training (HIIT) intervention (Christensen, Lehrskov, et al., 2019). This evidence concerns the gene IL6 and Abdominal obesity.